Indication
For the treatment of adult patients with visual impairment due to macular oedema secondary to branched and central retinal vein occlusion (BRVO and CRVO).
Medicine details
- Medicine name:
- faricimab (Vabysmo)
- SMC ID:
- SMC2685
- Pharmaceutical company
- Roche
- BNF chapter
- Eye
- Submission type
- Abbreviated
- Publication due date:
- 07 October 2024
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC